Related Experiment Video
Updated: Apr 4, 2026

Minimal Erythema Dose MED Testing
Published on: May 28, 2013
On Modelling Minimal Disease Activity
Christopher H Jackson1, Li Su1, Dafna D Gladman2
1MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge University, Cambridge, UK.
Objective:
To explore methods for statistical modelling of minimal disease activity (MDA) based on data from intermittent clinic visits.
Methods:
The analysis was based on a 2-state model. Comparisons were made between analyses based on "complete case" data from visits at which MDA status was known, and the use of hidden model methodology that incorporated information from visits at which only some MDA defining criteria could be established. Analyses were based on an observational psoriatic arthritis cohort.
Results:
With data from 856 patients and 7,024 clinic visits, analysis was based on virtually all visits, although only 62.6% provided enough information to determine MDA status. Estimated mean times for an episode of MDA varied from 4.18 years to 3.10 years, with smaller estimates derived from the hidden 2-state model analysis. Over a 10-year period, the estimated expected times spent in MDA episodes of longer than 1 year was 3.90 to 4.22, and the probability of having such an MDA episode was estimated to be 0.85 to 0.91, with longer times and greater probabilities seen with the hidden 2-state model analysis.
Conclusion:
A 2-state model provides a useful framework for the analysis of MDA. Use of data from visits at which MDA status can not be determined provide more precision, and notable differences are seen in estimated quantities related to MDA episodes based on complete case and hidden 2-state model analyses. The possibility of bias, as well as loss of precision, should be recognized when complete case analyses are used.
Related Concept Videos
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...
Clearance Models: Noncompartmental Models
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Rheumatic Heart Disease III: Medical Management

